The epidemiology of Clostridium difficile in Scotland

Journal of Infection

Volumn 62, Issue 4, 2011, Pages 271-279

  Wiuff, Camilla ^a   Brown, Derek J ^b   Mather, Henry ^b   Banks, A Lan ^a   Eastaway, Anne ^a   Coia, John E ^b  

^a HEALTH PROTECTION SCOTLAND   (United Kingdom)

^b STOBHILL HOSPITAL   (United Kingdom)

Author keywords

Antimicrobial resistance; Clostridium difficile; Epidemiology; PCR ribotypes

Indexed keywords

CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CHILD; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; HUMAN; INFANT; NONHUMAN; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD; UNITED KINGDOM;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EPIDEMICS; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; RIBOTYPING; SCOTLAND;

EID: 79953037219     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.01.015     Document Type: Article

References (32)

1. John R., Brazier J.S. Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 2005, 61(1):11-14.
2. Mutlu E., Wroe A.J., Sanchez-Hurtado K., Brazier J.S., Poxton I.R. Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. J Med Microbiol 2007, 56(Pt 7):921-929.
3. Brazier J.S., Patel B., Pearson A. Distribution of Clostridium difficile PCR ribotype 027 in British hospitals. Euro Surveill 2007, 12(4). E070426.
4. Kuijper E.J., Coignard B., Brazier J.S., Suetens C., Drudy D., Wiuff C., et al. Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill 2007, 12(6):E1-E2.
5. Annual report on the surveillance of Clostridium difficile associated disease (CDAD) in Scotland, October 2007-September 2008 2009, vol. 43. Health Protection Scotland, HPS Weekly Report, (2009/02) pp. 14-19.
6. Bauer M.P., Notermans D.W., van Benthem B.H., Brazier J.S., Wilcox M.H., Rupnik M., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377(9759):63-73.
7. Coia J.E. What is the role of antimicrobial resistance in the new epidemic of Clostridium difficile?. Int J Antimicrob Agents 2009, 33(Suppl. 1):S9-S12.
8. Gerding D.N. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004, 38(5):646-648.
9. O'Neill G.L., Ogunsola F.T., Brazier J.S., Duerden B.I. Modification of a PCR ribotyping method for application as a routine typing scheme for Clostridium difficile. Anaerobe 1996, 2:205-209.
10. Poilane I., Cruaud P., Torlotin J.C., Collignon A. Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile. Clin Microbiol Infect 2000, 6(3):155-156.
11. Anonymous. Organism Fact Sheet 1, Anaerobes:. [accessed 25.01.11]. Ref Type: Online Source. http://www.abbiodisk.com/pdf/etm_html/04_etm.htm.
12. Guidance on Prevention and control of Clostridium difficile infection (CDI) in healthcare settings in Scotland. Health Protection Network Scottish Guidance 2010, vol. 6. Health Protection Network, Health Protection Scotland.
13. Scottish Antimicrobial Prescribing Group (SAPG) - Report on antimicrobial resistance and use in humans in 2008 2010, Health Protection Scotland, Information Services Division Scotland.
14. Brazier J.S., Raybould R., Patel B., Duckworth G., Pearson A., Charlett A., et al. Distribution and antimicrobial susceptibility patterns of Clostridium difficile PCR ribotypes in English hospitals, 2007-08. Euro Surveill 2008, 13(41).
15. Wilcox M.H. Clostridium difficile Ribotyping Network for England and Northern Ireland 2008/09 Report 2009, on behalf of HPA Regional Microbiology Network, Health Protection Agency, London.
16. Barbut F., Mastrantonio P., Delmee M., Brazier J., Kuijper E., Poxton I. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007, 13(11):1048-1057.
17. Fenner L., Widmer A.F., Stranden A., Conzelmann M., Goorhuis A., Harmanus C., et al. First cluster of clindamycin-resistant Clostridium difficile PCR ribotype 027 in Switzerland. Clin Microbiol Infect 2008, 14(5):514-515.
18. Drudy D., Goorhuis B., Bakker D., Kyne L., van den Berg R., Fenelon L., et al. Clindamycin-resistant clone of Clostridium difficile PCR Ribotype 027, Europe. Emerg Infect Dis 2008, 14(9):1485-1487.
19. Zaiss N.H., Witte W., Nubel U. Fluoroquinolone resistance and Clostridium difficile, Germany. Emerg Infect Dis 2010, 16(4):675-677.
20. Wilcox M.H., Fawley W., Freeman J., Brayson J. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2000, 46(4):551-556.
21. Taori S.K., Hall V., Poxton I.R. Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004. J Med Microbiol 2010, 59(Pt 3):338-344.
22. Baines S.D., O'Connor R., Freeman J., Fawley W.N., Harmanus C., Mastrantonio P., et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008, 62(5):1046-1052.
23. Pelaez T., Cercenado E., Alcala L., Marin M., Martin-Lopez A., Martinez-Alarcon J., et al. Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 2008, 46(9):3028-3032.
24. Brazier J.S., Fawley W., Freeman J., Wilcox M.H. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001, 48(5):741-742.
25. Ackermann G., Tang-Feldman Y.J., Schaumann R., Henderson J.P., Rodloff A.C., Silva J., et al. Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. Clin Microbiol Infect 2003, 9(6):526-530.
26. Johnson S., Samore M.H., Farrow K.A., Killgore G.E., Tenover F.C., Lyras D., et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999, 341(22):1645-1651.
27. Pituch H., Brazier J.S., Obuch-Woszczatynski P., Wultanska D., Meisel-Mikolajczyk F., Luczak M. Prevalence and association of PCR ribotypes of Clostridium difficile isolated from symptomatic patients from Warsaw with macrolide-lincosamide-streptogramin B (MLSB) type resistance. J Med Microbiol 2006, 55(Pt 2):207-213.
28. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353(23):2442-2449.
29. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366(9491):1079-1084.
30. Kuijper E.J., Coignard B., Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006, 12(Suppl. 6):2-18.
31. Debast S.B., Vaessen N., Choudry A., Wiegers-Ligtvoet E.A., van den Berg R.J., Kuijper E.J. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect 2009, 15(5):427-434.
32. Deneve C., Bouttier S., Dupuy B., Barbut F., Collignon A., Janoir C. Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. Antimicrob Agents Chemother 2009, 53(12):5155-5162.